Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.

about

Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.

P2860

Q39280914-E4ADF502-3FB2-499B-89B1-6D18CB95415C

P2860

Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q40862682

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.

@en

type

Item

label

Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.

@en

prefLabel

Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.

@en

P1476

Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer

@en

P2093

Bin Zou

http://www.w3.org/2001/XMLSchema#string

Hong Yan

http://www.w3.org/2001/XMLSchema#string

Lichun Ma

http://www.w3.org/2001/XMLSchema#string

P2860

The Protein Data Bank

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

P304

1552-1563

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1039/C6MB00038J

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Guangyu Zhu

Debby D Wang

Victor Ho Fun Lee

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26961138

http://www.w3.org/2001/XMLSchema#string

Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.

about

P2860

P2860

Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698